These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit. Schneider DJ; Aggarwal A Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):903-13. PubMed ID: 15500435 [TBL] [Abstract][Full Text] [Related]
47. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related]
48. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Galli M; Maggioni AP; Vassanelli C; Tavazzi L Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377 [TBL] [Abstract][Full Text] [Related]
49. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G; Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353 [TBL] [Abstract][Full Text] [Related]
50. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion. Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490 [TBL] [Abstract][Full Text] [Related]
51. Comparative pharmacology of GP IIb/IIIa antagonists. Schrör K; Weber AA J Thromb Thrombolysis; 2003 Apr; 15(2):71-80. PubMed ID: 14618072 [TBL] [Abstract][Full Text] [Related]
52. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Jennings LK; Haga JH; Slack SM Thromb Haemost; 2000 Dec; 84(6):1095-102. PubMed ID: 11154119 [TBL] [Abstract][Full Text] [Related]
53. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. Berkowitz SD Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626 [TBL] [Abstract][Full Text] [Related]
55. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439 [TBL] [Abstract][Full Text] [Related]
56. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Mousa SA; Khurana S; Forsythe MS Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688 [TBL] [Abstract][Full Text] [Related]